Tetsu Tomonari

15PUBLICATIONS
45CO-AUTHORS
Medical biochemistry - lipidsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 28, 2026
Comparing the Effect of Changes in Alcohol Intake on Liver Fibrosis Risk Scores Among Patients With Two Distinct Types of Steatotic Liver Disease.

|Nov 28, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.

Ryu Sasaki, Shigeo Shimose, Issei Saeki

|Nov 14, 2025
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Takanori Ito, Shigeo Shimose, Issei Saeki

|May 07, 2025
Impact of muscle volume changes following atezolizumab-bevacizumab therapy in patients with unresectable hepatocellular carcinoma.

Hironori Ochi, Joji Tani, Tetsu Tomonari

|May 03, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.

Takanori Ito, Shigeo Shimose, Joji Tani

|Mar 07, 2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.

Tomoko Aoki, Masatoshi Kudo, Naoshi Nishida

Pageof 3

Frequent Collaborators

7 joint publications

Hironori Tanaka

4 joint publications

Tetsuji Takayama

4 joint publications

Yasushi Sato

4 joint publications

Takeshi Hatanaka